American Society Of Hematology

Women with venous thromboembolism associated with pregnancy, the postpartum period or combined oral contraceptives who have finished primary short-term treatment may be considered for thrombophilia testing.

SAN DIEGO — Infections are the main driver of mortality not related to disease relapse among individuals who received chimeric antigen receptor T cells, results of a meta-analysis presented at ASH Annual Meeting and Exhibition showed.

Alexis Thompson, MD, MPH, is an optimist.

SAN DIEGO — Axatilimab conferred clinically meaningful and durable responses at three dose levels among individuals with chronic graft-versus-host disease, randomized study results showed.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.

Healio spoke with Ryan. W. Jacobs, MD, about survivorship in CLL.

Three physicians have been elected to serve in leadership roles on ASH’s executive committee.

Thrombophilia is a known risk factor for venous thromboembolism, but the value of thrombophilia testing in guiding treatment decisions remains a topic of debate.

The FDA approved efanesoctocog alfa, a once-weekly treatment for children and adults with hemophilia A.

ASH announced the 36 recipients of the society’s 2022 Scholar Awards.